TYMS

Across TCGA pan-cancer cohorts, TYMS mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TYMS data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TYMS mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TYMS expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where TYMS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.283	0.571	.022	9	view →
CCRCC	DFS	Tertile	II,III,IV	0.744	0.305	.013	8	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	3	view →
GBM	OS	Median	All	0.559	0.270	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TYMS–PDAC (OS)

Open the PDAC breakdown →